Pudong, China

Xinxing Tang

USPTO Granted Patents = 4 

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2023-2025

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Xinxing Tang

Introduction

Xinxing Tang is a prominent inventor based in Pudong, China. He has made significant contributions to the field of chemotherapeutic agents, particularly focusing on heteroaromatic macrocyclic ether compounds. With a total of 4 patents to his name, Tang's work is paving the way for advancements in cancer treatment.

Latest Patents

Xinxing Tang's latest patents include innovative compounds that are designed to treat or prevent cancer. One of his notable patents discloses heterocyclic heteroaromatic macrocyclic ether compounds, along with their pharmaceutically acceptable salts and pharmaceutical compositions. This patent outlines methods for utilizing these compounds in cancer treatment. Another patent similarly focuses on heterocyclic heteroaromatic macrocyclic ether compounds of a specific formula, emphasizing their potential in pharmaceutical applications for cancer therapy.

Career Highlights

Tang is currently associated with Nuvalent, Inc., where he continues to develop groundbreaking solutions in the pharmaceutical industry. His expertise in chemotherapeutic agents has positioned him as a key figure in the fight against cancer.

Collaborations

Xinxing Tang collaborates with talented professionals in his field, including Joshua Courtney Horan and Scot Richard Mente. These partnerships enhance the innovative potential of his research and development efforts.

Conclusion

Xinxing Tang's contributions to the field of chemotherapeutic agents are noteworthy and impactful. His patents reflect a commitment to advancing cancer treatment through innovative research. The work he is doing at Nuvalent, Inc. is crucial for the future of pharmaceutical development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…